down arrow

Indaptus Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45339J1051
USD
2.50
0.36 (16.82%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.122.50

52 Week

1.6547.60
Valuation
Technical
Day's Volume

CASH

11.54 k

Shareholding (Mar 2025)

FII

0.03%

Held by 5 FIIs

DII

97.3%

Held by 3 DIIs

Promoter

0.00%

How big is Indaptus Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Indaptus Therapeutics, Inc. has a market capitalization of 5.11 million, with net sales of 0.00 million and a net profit of -15.75 million over the last four quarters. The company reported shareholder's funds of 3.94 million and total assets of 7.34 million as of Dec 24.

Market Cap: As of Jun 18, Indaptus Therapeutics, Inc. has a market capitalization of 5.11 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Indaptus Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -15.75 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 3.94 million and total assets of 7.34 million.

Read More

What does Indaptus Therapeutics, Inc. do?

22-Jun-2025

Indaptus Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $5.11 million. Key financial metrics indicate it is not profitable, with a negative P/E ratio and no dividend yield.

Overview:<BR>Indaptus Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 5.11 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.37 <BR>Return on Equity: -562.47% <BR>Price to Book: 1.83 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Indaptus Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, Indaptus Therapeutics shows a mildly bullish trend despite bearish signals from weekly indicators and significant underperformance with a year-to-date return of -89.10% compared to the S&P 500's 12.22%.

As of 20 August 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the monthly MACD being mildly bullish and the monthly RSI indicating bullish momentum. However, the weekly MACD, Bollinger Bands, KST, and Dow Theory all reflect bearish signals, which suggests underlying weakness. The daily moving averages are also bearish. <BR><BR>In terms of performance, Indaptus Therapeutics has significantly underperformed the S&P 500 across all time frames, with a year-to-date return of -89.10% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

966.54%

stock-summary
Price to Book

-1.92

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.31%
0%
-24.31%
6 Months
-74.26%
0%
-74.26%
1 Year
-90.7%
0%
-90.7%
2 Years
-95.86%
0%
-95.86%
3 Years
35.87%
0%
35.87%
4 Years
-98.29%
0%
-98.29%
5 Years
-99.38%
0%
-99.38%

Indaptus Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Indaptus Therapeutics, Inc. technically bullish or bearish?

As of 20 August 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the monthly MACD being mildly bullish and the monthly RSI indicating bullish momentum. However, the weekly MACD, Bollinger Bands, KST, and Dow Theory all reflect bearish signals, which suggests underlying weakness. The daily moving averages are also bearish. In terms of performance, Indaptus Therapeutics has significantly underperformed the S&P 500 across all time frames, with a year-to-date return of -89.10% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
3.99%
EBIT to Interest (avg)
-13.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.37
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.31%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.97
EV to EBIT
-0.10
EV to EBITDA
-0.10
EV to Capital Employed
-1.62
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-562.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (2.67%)

Foreign Institutions

Held by 5 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -30.00% vs -25.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-4.10",
          "chgp": "-9.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-4.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.60% vs -7.69% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.40",
          "val2": "-16.40",
          "chgp": "6.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-15.40",
          "chgp": "2.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.50
-4.10
-9.76%
Interest
0.00
0.00
Exceptional Items
-0.80
0.00
Consolidate Net Profit
-5.20
-4.00
-30.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -30.00% vs -25.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.40
-16.40
6.10%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.00
-15.40
2.60%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 2.60% vs -7.69% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Indaptus Therapeutics, Inc. stock-summary
stock-summary
Indaptus Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."